Outline
- Typical Phases of Drug Development and When Device Bridging Considerations Arise
- Possible Approaches to Reducing Regulatory Burden and Complexity
- Concept of PBBM-Safe Space
- Data Needed to Build a PBBM
- Role of PBBM in Device/Formulation Bridging Across Product Lifecycle
- Concept of PBBM-Safe Space
- Case Studies for Formulation and Device Bridging
- Key Take Aways
By Sandra Suarez-Sharp
ACCP 2026 Annual Meeting, September 27-29, 2026, North Bethesda, Maryland